Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:1/11/2019
Start Date:January 7, 2019
End Date:February 7, 2022
Contact:Stefania Chirita
Email:schirita@stanford.edu
Phone:650-723-1423

Use our guide to learn which trials are right for you!

Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer

This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying
cancer that has spread to the lymph nodes in patients with squamous cell head and neck
cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during
surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount
of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans
make detailed, computerized pictures of areas inside the body where the drug is used. Giving
panitumumab IRDye800 and 89Zr panitumumab to patients with head and neck cancer may help
doctors find metastatic lymph nodes better than current methods [positron emission tomography
(PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations].

Participants receive standard of care 18F-FDG-PET/CT and/or 18F-FDG-PET/MRI to assess their
cancer for surgical excision. Participants than receive panitumumab-IRDye800 dye and
89Zr-panitumumab, both by intravenous (IV) infusion, on Day 0. Participants will undergo
89Zr-panitumumab PET/CT imaging on Day 1 to 2, and then undergo surgical resection of the
tumor at 2 to 5 days after infusion. Participants with cancer-positive lymph nodes vs
cancer-negative lymph nodes will be analyzed as separate cohorts. Research imaging will be
performed intraoperatively using optical imaging devices and a high-energy gamma probe.
Subsequently, the excised tissue will evaluated ex vivo (back table) using radioactive
(89Zr-panitumumab) and fluorescence (panitumumab-IRDye800) imaging techniques. After surgery,
patients are followed up at 15 and 30 days.

PRIMARY OBJECTIVES:

I. Determine the sensitivity and specificity of zirconium Zr 89 panitumumab (89Zr
panitumumab) for the detection of tumor-involved regional lymph nodes.

SECONDARY OBJECTIVES:

I. Determine the number (proportion) of lymph nodes determined to be tumor positive by
histological and/or pathological evaluation that were NOT predicted tumor-positive by 89Zr
panitumumab labeling.

EXPLORATORY OBJECTIVES:

I. Determine the sensitivity and specificity of panitumumab IRDye800 for the detection of
tumor-involved regional lymph nodes.

II. Determine the number (proportion) of lymph nodes determined to be tumor positive by
histological and/or pathological evaluation that were NOT predicted tumor-positive by
panitumumab-IRdye800 labeling.

optical imaging devices listed in Appendix B intraoperative high-energy gamma probe.

Inclusion Criteria:

- Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.

- Subjects diagnosed with any T stage, any subsite within the head and neck that are
scheduled to undergo surgical resection. Subjects with recurrent disease or a new
primary will be allowed.

- Planned standard of care surgery with curative intent for squamous cell carcinoma.

- Hemoglobin ≥ 9 gm/dL.

- White blood cell count > 3000/mm³.

- Platelet count ≥ 100,000/mm³.

- Serum creatinine ≤ 1.5 times upper reference range.

Exclusion Criteria:

- Received an investigational drug within 30 days prior to first dose of
panitumumab-IRDye800.

- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
heart failure (CHF); significant liver disease; or unstable angina within 6 months
prior to enrollment.

- Previous bilateral neck dissection.

- History of infusion reactions to monoclonal antibody therapies.

- Pregnant or breastfeeding.

- Magnesium or potassium lower than the normal institutional values.

- Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.

- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.

- Severe renal disease or anuria.

- Known hypersensitivity to deferoxamine or any of its components.
We found this trial at
1
site
875 Blake Wilbur Drive
Palo Alto, California 94304
Principal Investigator: Eben L. Rosenthal
Phone: 650-723-2967
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials